GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Altman Z-Score

IsoPlexis (IsoPlexis) Altman Z-Score : -5.11 (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -5.11 is in distress zone. This implies bankruptcy possibility in the next two years.

IsoPlexis has a Altman Z-Score of -5.11, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for IsoPlexis's Altman Z-Score or its related term are showing as below:

ISO' s Altman Z-Score Range Over the Past 10 Years
Min: -5.11   Med: -0.71   Max: 3.41
Current: -5.11

During the past 4 years, IsoPlexis's highest Altman Z-Score was 3.41. The lowest was -5.11. And the median was -0.71.


IsoPlexis Altman Z-Score Historical Data

The historical data trend for IsoPlexis's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Altman Z-Score Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Altman Z-Score
- - 3.41 -4.83

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 -0.75 -2.02 -2.86 -4.83

Competitive Comparison of IsoPlexis's Altman Z-Score

For the Medical Devices subindustry, IsoPlexis's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IsoPlexis's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Altman Z-Score falls into.



IsoPlexis Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

IsoPlexis's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.4965+1.4*-2.2002+3.3*-0.9229+0.6*0.4467+1.0*0.1537
=-5.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2022:
Total Assets was $109.07 Mil.
Total Current Assets was $71.87 Mil.
Total Current Liabilities was $17.71 Mil.
Retained Earnings was $-239.97 Mil.
Pre-Tax Income was -33.212 + -18.455 + -25.606 + -28.725 = $-106.00 Mil.
Interest Expense was -1.663 + -1.485 + -1.21 + -0.986 = $-5.34 Mil.
Revenue was 3.361 + 4.484 + 4.005 + 4.911 = $16.76 Mil.
Market Cap (Today) was $30.28 Mil.
Total Liabilities was $67.80 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(71.865 - 17.711)/109.068
=0.4965

X2=Retained Earnings/Total Assets
=-239.97/109.068
=-2.2002

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-105.998 - -5.344)/109.068
=-0.9229

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=30.284/67.801
=0.4467

X5=Revenue/Total Assets
=16.761/109.068
=0.1537

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

IsoPlexis has a Altman Z-Score of -5.11 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


IsoPlexis  (NAS:ISO) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


IsoPlexis Altman Z-Score Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


IsoPlexis (IsoPlexis) Business Description

Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003